Thomas Richard Kassberg - 30 Sep 2024 Form 4 Insider Report for Passage BIO, Inc. (PASG)

Reporting relationship: Director
Issuer ticker: PASG
Reported as of: 30 Sep 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Oct 2024, 16:35:20 UTC
Prior SEC filing: 02 Oct 2024
Next SEC filing: 04 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Edgar Cale, Attorney-in-Fact

Key filing fact

Thomas Richard Kassberg filed Form 4 for Passage BIO, Inc. (PASG) on 02 Oct 2024.

Key facts

This page summarizes Thomas Richard Kassberg's Form 4 filing for Passage BIO, Inc. (PASG).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Oct 2024, 16:35.

Change

Previous filing in this sequence was filed on 02 Oct 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PASG transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +174,139
Change %
Price: $0.000000
Shares after: 174,139
Date: 30 Sep 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 174,139
Exercise price: $0.7000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option vests as to 1/36 of the total shares monthly beginning on October 10, 2024 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.